欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (6): 827-835.doi: 10.12092/j.issn.1009-2501.2026.06.012

• “糖尿病心血管并发症的药物进展”专栏 • 上一篇    

中药干预HMGB1通路改善2型糖尿病及其并发症的研究进展

卢爱琳1(), 袁梦蕊1, 吴永青1, 刘弘毅2()   

  1. 1. 云南中医药大学第一临床医学院,昆明 650051,云南
    2. 云南省中医医院 内分泌科,昆明 650021,云南
  • 收稿日期:2025-01-09 出版日期:2026-06-26 发布日期:2026-07-06
  • 作者简介:卢爱琳,在读硕士,研究方向:津液病的中医防治研究。E-mail:2903150093@qq.com|刘弘毅,博士,副教授,副主任医师,研究方向:津液病的中医药防治研究。E-mail:realliuhongyi@126.com
  • 基金资助:
    国家自然科学基金-地区科学基金项目(82360919);云南科技厅中医联合面上项目(202301AZ070001-066);云南省卫健委高层次中医药人才培养工作项目

Progress of Chinese medicine intervention in HMGB1 pathway to improve type 2 diabetes mellitus and its complications

Ailin LU1(), Mengrui YUAN1, Yongqing WU1, Hongyi LIU2()   

  1. 1. The First Clinical School of Medicine, Yunnan University of Traditional Chinese Medicine, Kunming 650051, Yunnan, China
    2. Department of Endocrinology, Yunnan Hospital of Traditional Chinese Medicine, Kunming 650021, Yunnan, China
  • Received:2025-01-09 Online:2026-06-26 Published:2026-07-06

摘要:

2型糖尿病(type 2 diabetes mellitus,T2DM)的发生与胰岛素抵抗和胰岛β细胞功能障碍密切相关,高迁移率族蛋白B1(high mobility group box 1,HMGB1)及其调控的相关受体和信号通路在T2DM及其并发症的发生发展中具有重要作用。HMGB1是炎症反应中的核心调节因子,广泛存在于肝脏、脂肪、骨骼肌以及胰岛等各类组织器官当中,主要通过增强炎症反应和加剧胰岛素抵抗等方式影响T2DM的病程。近年来,多种中药被证明可通过调控HMGB1及其相关受体和信号通路的表达,延缓T2DM及其并发症的进展。本文针对中药干预HMGB1通路改善T2DM及其并发症的国内外研究现状展开论述,旨在为未来运用中医药治疗T2DM及其相关并发症提供用药思路。

关键词: 高迁移率族蛋白B1, 2型糖尿病, 中药, 通路, 机制

Abstract:

The development of type2 diabetes mellitus (T2DM) is closely related to insulin resistance and pancreatic β-cell dysfunction, and high mobility group box 1 (HMGB1) and its related receptors and signaling pathways play an important role in the development of T2DM and its complications. HMGB1 is a core regulator of inflammatory response, widely found in various tissues and organs such as liver, adipose, skeletal muscle, and pancreatic islets, and affects the course of T2DM by enhancing inflammatory response and exacerbating insulin resistance. In recent years, a variety of traditional Chinese medicines (TCM) have been shown to slow down the progression of T2DM and its complications by regulating the expression of HMGB1 and its related receptors and signaling pathways. Therefore, the article discusses the current status of domestic and international research on the intervention of Chinese medicines in the HMGB1 pathway to improve T2DM and its complications, with the aim of providing medication ideas for the future use of Chinese medicines in the treatment of T2DM and its related complications.

Key words: high mobility group protein B1, type 2 diabetes mellitus, traditional Chinese medicine, pathway, mechanism

中图分类号: